Follow news, literature and expert opinions on GLP-1 as emerging target in the management of T2DM & Cardiovascular Disease
In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.
In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
In type 2 diabetes patients, semaglutide showed greater reductions of HbA1c and weight compared with liraglutide in the PIONEER 4 trial and compared with sitagliptin in the PIONEER 7 trial.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.
In the LEADER trial, patients with severe hypoglycemia episodes had a higher risk of CV events and mortality compared with patients without severe hypoglycemia, independent of treatment group.
Three cardiology and diabetes experts consider how the paradigma-shifting recent insights on the new antidiabetic drug classes can be implemented into clinical practice, which should involve a more multidisciplinary approach.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Results from the PIONEER 2 trial in T2DM patients demonstrated a significant and superior improvement in HbA1c with semaglutide compared to empagliflozin.
Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.
CME accredited symposium held at EuroPrevent 2018 in Ljubljana